EMBL scientists develop first fully automated pipeline for multiprotein complex production

06-May-2009 - France

Most cellular processes are carried out by molecular machines that consist of many interacting proteins. These protein complexes lie at the heart of life science research, but they are notoriously hard to study. Their abundance is often too low to extract them directly from cells and generating them with recombinant methods has been a daunting task. A new technology to produce multiprotein complexes, developed by researchers at the European molecular biology Laboratory (EMBL) in Grenoble, France, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, now makes the biologist's life easier.

In a paper published in the current issue of Nature Methods researchers of the groups of Imre Berger at EMBL and Michel Steinmetz at the PSI describe ACEMBL, the first fully automated pipeline for the production of multiprotein complexes. Requiring much less effort and materials, the new pipeline will speed up structural studies of protein complexes and will allow to decipher as yet elusive molecular mechanisms of health and disease.

ACEMBL can produce complexes consisting of different types of components, including protein, RNA and other biomolecules. Currently designed to express proteins in the standard system Escherichium coli, the automated pipeline will in future be adapted for complex production in eukaryotic cells. This will allow the study of even larger, more complicated complexes of human origin, including many promising drug targets. The system has already attracted commercial interest.

Other news from the department science

Most read news

More news from our other portals

Last viewed contents

Immunotope, Inc. - Doylestown PA, USA

Immunotope, Inc. - Doylestown PA, USA

Spin-off offers purification tool to tackle viral gene therapy manufacturing bottlenecks - Higher speed and increased yield thanks to membrane-based steric exclusion chromatography

Spin-off offers purification tool to tackle viral gene therapy manufacturing bottlenecks - Higher speed and increased yield thanks to membrane-based steric exclusion chromatography

One in six college students misuse ADHD stimulant drugs

One in six college students misuse ADHD stimulant drugs

NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD

Herpes virus to be weaponized to fight cancer - Viral immunotherapy could also prove effective against metastases

Herpes virus to be weaponized to fight cancer - Viral immunotherapy could also prove effective against metastases

New gene transporter to trick the immune system - Junior scientist receives 60.000 euro prize for research on haemophilia A therapy

New gene transporter to trick the immune system - Junior scientist receives 60.000 euro prize for research on haemophilia A therapy

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

BioServe - Beltsville, USA

BioServe - Beltsville, USA

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

Boehringer Ingelheim announces change in the company management - Harsha Deshmukh has been appointed as a member of the Executive Board with responsibility for IT and Global Business Services with effect from February 1, 2026

BIOTECON Diagnostics GmbH and Xiril AG start worldwide sales cooperation

More evidence that melanoma does not conform to the cancer stem cell model

Vitamin D benefits breathing in tuberculosis patients - Large-scale study finds vitamin supports lung function as well as bone health